• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pharmaceutical Contract Manufacturing - Global Strategic Business Report Product Image

Pharmaceutical Contract Manufacturing - Global Strategic Business Report

  • ID: 347965
  • June 2014
  • Region: Global
  • 185 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments).

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 92 companies including many key and niche players such as:

- AAIPharma Services Corporation
- Aenova Group
- Ajinomoto Althea, Inc.
- Albany Molecular Research, Inc.
- Dishman

PHARMACEUTICAL CONTRACT MANUFACTURING MCP-1535 A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

A Curtain Raiser
Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production
Key Market Drivers
Biopharma Contract Manufacturing Market Emerges from the Recessionary Lull
Table 1: Worldwide Funding for Biotech Projects by Geographic Region (2012): Percentage Breakdown of Funding for North America, Europe, and Rest of World (includes corresponding Graph/Chart)
Table 2: Worldwide Funding for Biotech Projects by Product Development Phase (2012): Percentage Breakdown of Funding for Products in Clinical Trial, Pre-Clinical Trial and Commercialization Phases (includes corresponding Graph/Chart)
Favorable Trends in the Pharma Industry Portend Bright Outlook for the PCM Market
Ballooning Global Population Offers Increased Growth Opportunities
Table 3: Top 25 Countries Worldwide in Terms of Population: 2007, 2010 & 2013
Surge in Generic Drugs to Benefit Pharmaceutical Contract Manufacturers
Table 4: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart)
Increasing Consumption Drugs within Aging Population Boosts Opportunities for PCM
Table 5: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
Table 6: Elderly Population (65+ Years) as a % of Total Population (2025) (includes corresponding Graph/Chart)
Changing Healthcare Expenditure Trends to Spur Demand for Contract Manufacturing of Generics
Table 7: Healthcare Spending as a Percentage of GDP: 2012 (includes corresponding Graph/Chart)
US and Europe Dominate Market, Asia-Pacific Lends Growth Momentum
Major Changes Imperative to Capitalize on Brighter Future Prospects
Solid Dosage Form Retains Popularity among Pharma Contract Manufacturers
Injectable-Dose Formulations to Spearhead Growth of the PCM Market

2. MAJOR MARKET TRENDS & ISSUES

Patent Expiries Augur Good Tidings for the PCM Market
PCMs Gear Up to Tap Booming Biologics Market
PCM Market for Vaccines Yet to Take Off
Biotechnology Upstarts Spur Demand for Contract Manufacturing
Vendor Switching- A Growing Concern for PCMs
Marked Decrease Witnessed in Venture Capital Investment into PCM Upstarts
PCM Industry Gravitates Eastward, and Subsequently Leads to Near-Shoring
Adoption of Cutting-Edge Technologies to Radicalize PCM Environment
RABS technology
Quality by Design
Track & Trace Techniques
Disposable Processing Techniques
Upstream & Downstream Processes
Process Analytical Technology
Near Infrared Spectroscopy
Increased Regulator Scrutiny: A Cause of Concern for the Emerging Market PCMs

3. COMPETITIVE LANDSCAPE

PCM
A Highly Fragmented Industry Undergoing Consolidation
Table 8: Worldwide Pharmaceutical Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Catalent Pharma Solutions, DPx Holdings B.V., Famar Health Care Services, and Others (includes corresponding Graph/Chart)
Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart)
PCMs Battle Fierce Competition and Commoditization
Large Enterprises Edging Out Small-scale Players
Competitive Pricing Pressure to Spur Consolidation
Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service Offerings

4. SERVICE OVERVIEW

Introduction
Injectables (Injections, Vials, and IV solutions)
Solid Dosage Forms (SDFs) (Tablets and Capsules)
Liquid Dosage Forms (LDFs) (Syrups and Suspensions)
An Insight into the Rise of Pharmaceutical Contract Manufacturing
Investment Risks in Pharmaceutical Contract Manufacturing
Quality Assurance Risk
Drug Development Risk
Acquisition Risk
Client Dependency Risk

5. RECENT INDUSTRY ACTIVITY

Onyx Announces completion of API project with Neuronascent
Meiji Holdings Buys Medreich Lifecare Limited
Emilia Group Takes Over Pharma Pac LLC
AMRI to Take Over Cedarburg Pharma
AMRI to Acquire OsoBio Biopharmaceuticals Manufacturing
Royal DSM’s DPP Merges with JLL Partners’ Pantheon, Giving Rise to DPx Holdings B.V.
Emergent BioSolutions Takes Over Cangene Corporation
Dendreon Appoints PharmaCell as European CMO
Ajinomoto Acquires Althea Technologies
Aenova Group Merges with Haupt Pharma
Kemwell Biopharma Takes Over Cirrus Pharmaceuticals
Questcor Acquires BioVectra
ICON Buys Cross Country Healthcare’s Clinical Trial Services Division
Columbia Laboratories Acquires Molecular Profiles
EPS Corp Acquires Gleneagles CRC from IHH Healthcare
Capsugel to Take Over Bend Research
Gallus BioPharmaceutical Takes Over Laureate Biopharmaceutical
PLI Holdings Acquires Pfanstiehl Laboratories
DPT Laboratories Announce Integration With Confab
Nordion Inks Contract Manufacturing Agreement with Navidea
Unilife Receives Injectables Contract from Hikma
NextPharma Technologies Expands Bielefeld Production Capacity and Capabilities
Fuji Pharma to Acquire OLIC from DKSH
DSM Pharmaceutical Partners Almac Group
Metrics Inc Introduces Generic Drug of Oxycodone HCl 5mg
Patheon Completes Acquires Banner Pharmacaps
PAREXEL International Acquires Liquent
American Capital Acquires Cambridge Major
Aenova Group Takes Over Euro Vital Pharma
Althea Technologies Receives Contract from Pfenex

6. FOCUS ON SELECT GLOBAL PLAYERS

AAIPharma Services Corporation (US)
Aenova Group (Germany)
Haupt Pharma AG (Germany)
Ajinomoto Althea, Inc. (US)
Albany Molecular Research Inc. (US)
Boehringer Ingelheim GmbH (Germany)
Catalent Pharma Solutions, Inc. (US)
Dishman (India)
DPx Holdings B.V. (US)
Famar Health Care Services (Greece)
Hospira, Inc. (US)
Jubilant Life Sciences Limited (India)
Kemwell Biopharma Pvt. Ltd (India)
Lonza Group Ltd. (Switzerland)
NextPharma Technologies Holding Ltd (UK)
Nipro Pharma Corporation (Japan)
Recipharm AB (Sweden)
Cobra Biologics Holding AB (Sweden)

7. GLOBAL MARKET PERSPECTIVE

Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 11: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 12: World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 13: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 15: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 18: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 21: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A.Market Analysis
US PCM Market Overview
Competitive Landscape
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 22: The US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 23: The US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 24: The US 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

2. CANADA

A.Market Analysis
Strategic Corporate Developments
B.Market Analytics
Table 25: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 26: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 27: Canadian 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

3. JAPAN

A.Market Analysis
Strategic Corporate Development
Nipro Pharma Corporation
A Key Japanese Player
B.Market Analytics
Table 28: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 29: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 30: Japanese 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4. EUROPE

A.Market Analysis
European PCM Market Caught in Eurodebt Doldrums
Injectables Segment Offers Promising Potential
Mammalian Cell Technology Dominates PCM Market
Competitive Scenario
Overview of Select Markets
Germany
Russia
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 31: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 32: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 33: European 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A.Market Analysis
Favorable Government Policies Transform China and India into PCM Hubs
Competitive Scenario
Overview of Select Regional Markets
China
Outsourcing Industry Bogged Down by Recession
India
Indian PCMs Battle Soaring Costs
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 34: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 35: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 36: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

6. REST OF WORLD

Market Analysis
Table 37: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 38: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 39: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 92 The United States (34)
Canada (3)
Japan (4)
Europe (33)
France (3)
Germany (8)
The United Kingdom (9)
Italy (3)
Rest of Europe (10)
Asia-Pacific (Excluding Japan) (18)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos